Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is Shenzhen Neptunus Interlong Bio-Technique Co Quick Ratio?
Shenzhen Neptunus Interlong Bio-Technique CoHKSE:08329 -5.71% Quick Ratio is 1.50 as of Jun. 2026, which is 18% below its 10-year median of 1.84. The stock has 3 warning signs investors should review. Among 998 Drug Manufacturers companies, Shenzhen Neptunus Interlong Bio-Technique Co ranks better than 53.71% on this metric.
Shenzhen Neptunus Interlong Bio-Technique Co (HKSE:08329) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Shenzhen Neptunus Interlong Bio-Technique Co Quick Ratio Related Terms
Shenzhen Neptunus Interlong Bio-Technique Co Quick Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shenzhen Neptunus Interlong Bio-Technique Co Quick Ratio Chart
Shenzhen Neptunus Interlong Bio-Technique Co Annual Data
For the Drug Manufacturers - Specialty & Generic subindustry, Shenzhen Neptunus Interlong Bio-Technique Co's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shenzhen Neptunus Interlong Bio-Technique Co Quick Ratio vs Drug Manufacturers Industry
Shenzhen Neptunus Interlong Bio-Technique Co Quick Ratio Calculation
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shenzhen Neptunus Interlong Bio-Technique Co (HKSE:08329) has a Quick Ratio of 1.50 as of Jun. 2026. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Shenzhen Neptunus Interlong Bio-Technique Co and its competitors. This is 18% below median its historical median of 1.84. Over the past decade, Shenzhen Neptunus Interlong Bio-Technique Co's Quick Ratio has ranged from 1.48 to 3.40. According to the industry distribution chart, Shenzhen Neptunus Interlong Bio-Technique Co ranks #462 out of 998 companies in the Drug Manufacturers industry, placing it in the top 46.3%.
Is Shenzhen Neptunus Interlong Bio-Technique Co's Quick Ratio too high?
Shenzhen Neptunus Interlong Bio-Technique Co's current Quick Ratio of 1.50 is 18% below median its 10-year median of 1.84. Over the past 10 years, this metric has ranged from a low of 1.48 to a high of 3.40. The Drug Manufacturers industry median Quick Ratio is 1.40. Shenzhen Neptunus Interlong Bio-Technique Co's value of 1.50 is 7.1% above this industry median. Based on the distribution chart, Shenzhen Neptunus Interlong Bio-Technique Co ranks #462 out of 998 companies in the Drug Manufacturers industry, which is above the industry midpoint.
How does Shenzhen Neptunus Interlong Bio-Technique Co's Quick Ratio compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Shenzhen Neptunus Interlong Bio-Technique Co ranks #462 out of 998 companies for Quick Ratio. This puts Shenzhen Neptunus Interlong Bio-Technique Co in the upper half of its industry. The industry median Quick Ratio is 1.40. Shenzhen Neptunus Interlong Bio-Technique Co's value of 1.50 is 7.1% above this benchmark. Historically, Shenzhen Neptunus Interlong Bio-Technique Co's own Quick Ratio has ranged from 1.48 to 3.40 over the past decade. While the company's 10-year median is 1.84 vs. the industry median of 1.40, Shenzhen Neptunus Interlong Bio-Technique Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Drug Manufacturers company?
The median Quick Ratio among Drug Manufacturers companies is 1.40, based on 998 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shenzhen Neptunus Interlong Bio-Technique Co's current Quick Ratio of 1.50 is 7.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Shenzhen Neptunus Interlong Bio-Technique Co and its competitors. For the Drug Manufacturers industry, the median Quick Ratio is 1.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shenzhen Neptunus Interlong Bio-Technique Co's current Quick Ratio is 1.50, which is 18% below median its own 10-year median of 1.84. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shenzhen Neptunus Interlong Bio-Technique Co stock overvalued right now?
Based on GuruFocus' analysis, Shenzhen Neptunus Interlong Bio-Technique Co (HKSE:08329) is currently considered Modestly Undervalued. The stock's GF Value™ is HK$0.14, compared to a current price of HK$0.10 — trading 29.3% below its estimated fair value. The current Quick Ratio is 1.50, which is 18% below median its 10-year median of 1.84 and 7.1% above the Drug Manufacturers industry median of 1.40. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Shenzhen Neptunus Interlong Bio-Technique Co (HKSE:08329), the current Quick Ratio is 1.50 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Shenzhen Neptunus Interlong Bio-Technique Co Ltd is engaged in the research and development, manufacturing, and selling of medicines and medical devices. It is also involved in the purchase and sale of medicines and healthcare food products. The group's revenue and results from operations are mainly derived from activities in the PRC. The operating segments of the company are the Manufacturing and selling of medicines and medical devices; and the Sales and distribution of medicines, healthcare products, and medical devices.. The majority of revenue is generated from the Manufacturing and selling of medicines and medical devices segment.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:08329 has been successfully added to your 
